Recce's unapproved drug proves successful treatment for life-threatening illness

07AprApril 7, 2021

Recce’s unapproved drug proves successful treatment for life-threatening illness

Superbug and viral pathogen treatment developer Recce Pharmacetical (ASX:RCE)’s unapproved drug R327 has successfully saved a patient suffering a life-threatening illness.

Despite not undertaking clinical trials, nasal treatment R327 was accessible to the individual via Category A of the Therapeutic Goods Administration special access scheme. Recce (ASX:RCE) intends to proceed with clinical trials for the product.

The news has shot Recce’s shares up 5.1 per cent to $1.03
Copyright 2021 – Finance News Network

Source: Finance News Network

05MayMay 5, 2023

Stocks of the Hour: Splitit Payments, ImpediMed, Magnetite Mines

05 May 2023 - A snapshot of the stocks on the move featuring Splitit Payments (ASX:SPT), ImpediMed Limited (ASX:IPD) and Magnetite Mines (ASX:MGT).

30JanJanuary 30, 2023

Stocks of the Hour: Magmatic Resources, BluGlass, Babylon Pump & Power

30 Jan 2023 - A snapshot of the stocks on the move featuring Magmatic Resources (ASX:MAG), BluGlass (ASX:BLG) and Babylon Pump & Power (ASX:BPP).

19SepSeptember 19, 2024

Stocks of the Hour: Javelin Minerals, Bindi Metals, GreenTech Metals

19 Sep 2024 - A snapshot of the stocks on the move, featuring Javelin Minerals (ASX:JAV), Bindi Metals (ASX:BIM) and GreenTech Metals (ASX:GRE).

21AugAugust 21, 2020

Suncorp Group (ASX:SUN) NPAT up 422% YoY

21 Aug 2020 - Suncorp Group net profit after tax was up around 422% year on year to $913 million.

24MayMay 24, 2022

Snap dives 28% pulling ASX tech giants lower on rising inflation

24 May 2022 - Snap’s share price dived over 28% after an earnings miss, warning investors of a hiring slowdown with the Nasdaq futures falling 1.3% as investors fret about tech giant’s reliance on internet advertising. The news pulled Facebook-owner Meta Platforms and Google-owner Alphabet down 7 and almost 4% respectively.